Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Rated “Moderate Buy” by Wall Street Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $29.00.

Several research firms recently weighed in on KMTS. Evercore started coverage on Kestra Medical Technologies in a report on Tuesday, October 20th. They set an “outperform” rating and a $34.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a report on Wednesday, July 15th.

Insider Buying and Selling at Kestra Medical Technologies

In related news, CFO Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44. Following the sale, the chief financial officer directly owned 60,609 shares in the company, valued at $1,847,362.32. This trade represents a 39.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alfred Ford, Jr. sold 13,015 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $23.90, for a total transaction of $311,058.50. Following the sale, the insider directly owned 105,839 shares in the company, valued at $2,529,552.10. The trade was a 10.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 399,694 shares of company stock worth $10,842,727 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC increased its holdings in Kestra Medical Technologies by 834.0% in the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after purchasing an additional 784 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Kestra Medical Technologies during the 3rd quarter worth $353,000. Quantinno Capital Management LP bought a new position in Kestra Medical Technologies during the 1st quarter worth $431,000. California State Teachers Retirement System raised its position in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth about $603,000.

Kestra Medical Technologies Stock Performance

Shares of Kestra Medical Technologies stock opened at $29.69 on Tuesday. Kestra Medical Technologies has a fifty-two week low of $17.34 and a fifty-two week high of $31.06. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a market capitalization of $1.77 billion, a P/E ratio of -11.12 and a beta of 0.51. The company’s 50 day moving average price is $26.69 and its two-hundred day moving average price is $23.82.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The company had revenue of $30.97 million for the quarter. On average, equities analysts forecast that Kestra Medical Technologies will post -2.45 earnings per share for the current fiscal year.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.